Aktienanalyse zu Mineralys Therapeutics Inc (MLYS)MLYSMineralys Therapeutics Inc

Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as CKD and OSA. Lorundrostat is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone. It has completed the Target-HTN trial, a Phase II proof-of-concept trial for lorundrostat in the treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN). It is also investigating the benefits of lorundrostat in subjects with hypertension and CKD and with hypertension and OSA. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $20.30 and an RSI of 27.989, which indicates the stock is oversold, it may seem like a potential buy. However, the company has reported significant losses, with a net income of -241 million USD in Q2 2026 and a year-to-date change of -43.15%. Additionally, insider selling activity, while strategic, raises concerns about confidence in the stock. Therefore, the risks outweigh the potential rewards at this time.